Literature DB >> 16641428

Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?

David C Griffith1, Erik Corcoran, Denene Lofland, Angela Lee, Deidre Cho, Olga Lomovskaya, Michael N Dudley.   

Abstract

The Pseudomonas aeruginosa efflux pumps MexAB-OprM, MexCD-OprJ, and MexEF-OprN play an important role in susceptibility to fluoroquinolones in vitro. To determine if levofloxacin MICs arising from different levels of expression of efflux pumps result in a proportional reduction in the response to levofloxacin in vivo, isogenic strains of P. aeruginosa were tested with levofloxacin in two mouse models of infection (sepsis and neutropenic mouse thigh models). The levofloxacin 50% effective doses (ED(50)s) increased proportionally with the MICs for most strains. Similarly, the 24-h area under the concentration-time curve (AUC)/MIC ratio that resulted in 90% of the maximum bactericidal activity (90% E(max)) exceeded 75 for all strains except those with elevated MICs due to MexEF-OprN overexpression. In these strains, levofloxacin ED(50)s were 2- to 10-fold lower than the ED(50)/MIC ratios in the other strains and 90% E(max) AUC/MIC ratios were 2- to 4-fold lower than those predicted from pharmacodynamic modeling of efficacy against other strains. These data show that while the MexEF-OprN efflux pump can provide P. aeruginosa resistance to levofloxacin in vitro, it appears to be less efficient in providing resistance to levofloxacin in animal models of infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16641428      PMCID: PMC1472187          DOI: 10.1128/AAC.50.5.1628-1632.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides.

Authors:  J R Aires; T Köhler; H Nikaido; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.

Authors:  P G Ambrose; D M Grasela; T H Grasela; J Passarell; H B Mayer; P F Pierce
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

3.  Rapid and accurate determination of the median lethal dose (LD50) and its error with a small computer.

Authors:  A P Rosiello; J M Essignmann; G N Wogan
Journal:  J Toxicol Environ Health       Date:  1977-12

4.  Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa.

Authors:  O Lomovskaya; A Lee; K Hoshino; H Ishida; A Mistry; M S Warren; E Boyer; S Chamberland; V J Lee
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.

Authors:  O Lomovskaya; M S Warren; A Lee; J Galazzo; R Fronko; M Lee; J Blais; D Cho; S Chamberland; T Renau; R Leger; S Hecker; W Watkins; K Hoshino; H Ishida; V J Lee
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

6.  Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon.

Authors:  K Poole; K Krebes; C McNally; S Neshat
Journal:  J Bacteriol       Date:  1993-11       Impact factor: 3.490

7.  Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa.

Authors:  T Yoshida; T Muratani; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

8.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.

Authors:  N N Teng; H S Kaplan; J M Hebert; C Moore; H Douglas; A Wunderlich; A I Braude
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  Isolation of OprM-deficient mutants of Pseudomonas aeruginosa by transposon insertion mutagenesis: evidence of involvement in multiple antibiotic resistance.

Authors:  N Gotoh; N Itoh; H Tsujimoto; J Yamagishi; Y Oyamada; T Nishino
Journal:  FEMS Microbiol Lett       Date:  1994-10-01       Impact factor: 2.742

10.  Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.

Authors:  A Forrest; D E Nix; C H Ballow; T F Goss; M C Birmingham; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more
  10 in total

Review 1.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

2.  Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.

Authors:  David E Geller; Patrick A Flume; David C Griffith; Elizabeth Morgan; Dan White; Jeffery S Loutit; Michael N Dudley
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

Review 3.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 4.  Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance.

Authors:  Lucía Fernández; Robert E W Hancock
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

5.  Role of the MexEF-OprN efflux system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin.

Authors:  Catherine Llanes; Thilo Köhler; Isabelle Patry; Barbara Dehecq; Christian van Delden; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2011-09-12       Impact factor: 5.191

6.  Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria.

Authors:  Vincent Hernandez; Thibaut Crépin; Andrés Palencia; Stephen Cusack; Tsutomu Akama; Stephen J Baker; Wei Bu; Lisa Feng; Yvonne R Freund; Liang Liu; Maliwan Meewan; Manisha Mohan; Weimin Mao; Fernando L Rock; Holly Sexton; Anita Sheoran; Yanchen Zhang; Yong-Kang Zhang; Yasheen Zhou; James A Nieman; Mahipal Reddy Anugula; El Mehdi Keramane; Kingsley Savariraj; D Shekhar Reddy; Rashmi Sharma; Rajendra Subedi; Rajeshwar Singh; Ann O'Leary; Nerissa L Simon; Peter L De Marsh; Shazad Mushtaq; Marina Warner; David M Livermore; M R K Alley; Jacob J Plattner
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

7.  The Nonantibiotic Macrolide EM703 Improves Survival in a Model of Quinolone-Treated Pseudomonas aeruginosa Airway Infection.

Authors:  Gopinath Kasetty; Ravi K V Bhongir; Praveen Papareddy; Heiko Herwald; Arne Egesten
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.

Authors:  Rajbharan Yadav; Jürgen B Bulitta; Jiping Wang; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

9.  Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.

Authors:  Mojgan Sabet; Courtney E Miller; Thomas G Nolan; Kathy Senekeo-Effenberger; Michael N Dudley; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

Review 10.  Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa.

Authors:  Jürg Dreier; Paolo Ruggerone
Journal:  Front Microbiol       Date:  2015-07-08       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.